Bone Marrow-Derived Cells: From the Laboratory to the Clinic

J. Xie, K. L. March, M. P. Murphy

Research output: Chapter in Book/Report/Conference proceedingChapter


Bone marrow mononuclear cells (BMMNC) are enriched with a variety of angiogenic stem and progenitor cells, as well as mature hematopoietic cells that function synergistically to promote neovascularization. Delivery of BMMNC or its subpopulations have demonstrated marked effects on revascularization of ischemic tissue in preclinical models. Extensive phase-I and -II clinical trials in critical limb ischemia (CLI) patients have established the safety of BMMNC and showed promising effects of the cells to improve ischemic pain, ulcer size, pain-free walking distance, ABI, and TcPO2, while phase-III randomized control trials (RCT) are rapidly unfolding. This chapter introduces the concept of BMMNC and its subpopulations in the context of peripheral arterial disease. It also discusses the animal models of CLI in which mechanisms of bone marrow-derived cells were investigated. Finally, the progress in the clinical trials using BMMNC to treat CLI patients were summarized and the challenges were discussed.

Original languageEnglish (US)
Title of host publicationRegenerative Medicine for Peripheral Artery Disease
PublisherElsevier Inc.
Number of pages16
ISBN (Print)9780128013441
StatePublished - Jun 13 2016


  • Animal model
  • Bone marrow mononuclear cell
  • Clinical trial
  • Endothelial progenitor cells
  • Hematopoietic stem cell
  • Peripheral arterial disease

ASJC Scopus subject areas

  • Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Bone Marrow-Derived Cells: From the Laboratory to the Clinic'. Together they form a unique fingerprint.

  • Cite this

    Xie, J., March, K. L., & Murphy, M. P. (2016). Bone Marrow-Derived Cells: From the Laboratory to the Clinic. In Regenerative Medicine for Peripheral Artery Disease (pp. 27-42). Elsevier Inc..